Detalhe da pesquisa
1.
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.
Lancet
; 399(10328): 909-923, 2022 03 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35248186
2.
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Lung
; 200(4): 423-429, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35895098
3.
Efficacy and Safety of Gefapixant for Refractory or Unexplained Chronic Cough over 52 Weeks.
Am J Respir Crit Care Med
; 207(11): 1539-1542, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36996347
4.
Development of a Report Card for Identifying Local Sublingual Immunotherapy Events in Clinical Trials.
Patient
; 10(4): 439-446, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28161735